This pharma name targeting aging has soared this year. BTIG thinks it can double from here

BioAge Labs could more than double amid the release of more data on its anti-inflammation and weight loss drugs over the next year, according to BTIG. The investment firm initiated coverage of the biopharmaceutical name with a buy rating. It also set a $40 price target on shares, implying 120% upside from Tuesday's close. …